key: cord-0996527-y6jrt5xh authors: Savinkina, A.; Bilinksi, A.; Fitzpatrick, M. C.; Paltiel, A. D.; Rizvi, Z.; Salomon, J. A.; Thornhill, T.; Gonsalves, G. S. title: Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era date: 2022-02-09 journal: nan DOI: 10.1101/2022.02.08.22270465 sha: be74bc39453e5786675746efe6b341863ca9e97d doc_id: 996527 cord_uid: y6jrt5xh Background: While almost 60% of the world has received at least one dose of COVID-19 vaccine, the global distribution of vaccination has not been equitable. Only 4% of the population of low-income countries has received a full primary vaccine series, compared to over 70% of the population of high-income nations. Methods: We used economic and epidemiologic models, parameterized with public data on global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up vaccination programs in low and lower-middle income countries (LIC/LMIC) in 2022 in the context of global spread of the Omicron variant of SARS-CoV2. Outcomes were expressed as number of avertable deaths through vaccination, costs of scale-up, and cost per death averted. We conducted sensitivity analyses over a wide range of parameter estimates to account for uncertainty around key inputs. Findings: Global scale up of vaccination to provide two doses of mRNA vaccine to everyone in LIC/LMIC would cost $35.5 billion and avert 1.3 million deaths from COVID-19, at a cost of $26,900 per death averted. Scaling up vaccination to provide three doses of mRNA vaccine to everyone in LIC/LMIC would cost $61.2 billion and avert 1.5 million deaths from COVID-19 at a cost of $40,800 per death averted. Lower estimated infection fatality ratios, higher cost-per-dose, and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in the analysis. Interpretation: Scaling up COVID-19 global vaccination would avert millions of COVID-19 deaths and represents a reasonable investment in the context of the value of a statistical life (VSL). Given the magnitude of expected mortality facing LIC/LMIC without vaccination, this effort should be an urgent priority. of low-income countries has received a full primary vaccine series, compared to over 70% of the 23 population of high-income nations. 24 25 Methods: We used economic and epidemiologic models, parameterized with public data on 26 global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up 27 vaccination programs in low and lower-middle income countries (LIC/LMIC) in 2022 in the 28 context of global spread of the Omicron variant of SARS-CoV2. Outcomes were expressed as 29 number of avertable deaths through vaccination, costs of scale-up, and cost per death averted. 30 We conducted sensitivity analyses over a wide range of parameter estimates to account for 31 uncertainty around key inputs. 32 33 Findings: Global scale up of vaccination to provide two doses of mRNA vaccine to everyone in 34 LIC/LMIC would cost $35.5 billion and avert 1.3 million deaths from COVID-19, at a cost of 35 $26,900 per death averted. Scaling up vaccination to provide three doses of mRNA vaccine to 36 everyone in LIC/LMIC would cost $61.2 billion and avert 1.5 million deaths from COVID-19 at 37 a cost of $40,800 per death averted. Lower estimated infection fatality ratios, higher cost-per-38 dose, and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in 39 the analysis. As of January 7 2022, 59% of the global population had received at least one dose of a COVID-50 19 vaccine, 50% had received a full primary vaccine course, and 7% had received an additional 51 booster. In low-income countries, 1 only 9% of people had received any dose of vaccine, and only 52 4% had received two doses. 2 The barriers to global access to COVID-19 vaccines have been 53 well-described. Many have emphasized the need to scale-up mRNA vaccine production to 54 remedy these, including the transfer of technology for vaccine production to regional hubs to 55 scale-up supply more quickly as recommend by the World Health Organization. 3,4 Beyond 56 humanitarian implications, lingering inequities in access to COVID-19 vaccines will delay the 57 worldwide recovery from the pandemic and continue to fuel the rise of new variants as the virus 58 spreads in many parts of the globe. 5 59 60 Because the most dire complications of COVID-19 occur in older people and the age structure in 61 many developing countries skews relatively young, it was initially assumed that the mortality 62 burden in low (LIC) and lower-middle income countries ( . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10. 1101 /2022 Organization is already setting up an mRNA production hub, 16 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2022. country, and the IFR to estimate a "number of avertable deaths" for future death from COVID-156 19, assuming those who are previously vaccinated and those who have previous immunity are 157 protected at least in part. Third, we predicted the number of deaths that could be prevented based 158 on estimated vaccine effectiveness. 159 160 We evaluated two potential dosage scenarios, one which estimates cost and effect of global 161 vaccination with two doses of mRNA vaccine ("two-dose scenario"), and one with three doses of 162 mRNA vaccine, the primary full course plus an additional booster ("three-dose scenario"). The 163 two-dose scenario assumes that everyone who is unvaccinated at the start of the simulation will 164 receive two doses, and those with one vaccine dose will receive an additional dose. The three-165 dose scenario calculation assumes those who are unvaccinated will receive three doses, those 166 with two doses will receive one additional dose, and those with one dose will receive two 167 additional doses. For cost calculations, we multiplied the number of doses needed for full 168 population vaccination under these dosage scenarios by the cost per dose. 169 170 We estimated the number previously infected with COVID-19 in each region using estimates of 171 regional COVID-19-related mortality and IFR: 172 Ii is the proportion of the population in region i with previous COVID-19 infection, Mi is the 177 number of deaths attributed to COVID-19 since March 2020, IFRpO is the infection fatality rate 178 of COVID-19 pre-Omicron, and Pi is the population of region i. 179 180 As mortality due to COVID-19 is not well-measured in most LIC/LMIC, we estimate in two 181 ways. One method uses reported COVID-19 deaths as the COVID-19 mortality estimate, with 182 the understanding that this would likely underestimate mortality due to Alternatively, we use excess deaths estimates as the indicator of COVID-19 mortality. 11 The 184 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270465 doi: medRxiv preprint modeled estimates of excess death have wide confidence intervals, and therefore we use both the 185 median estimate and the 95% confidence limits in our analyses to reflect this uncertainty. 186 187 We estimated the number of potentially avertible deaths ( , ) from COVID-19 based on prior 188 immunity and prior vaccination in each region with the two-dose and three-dose scenario: 189 190 For two-dose scenario: For three-dose scenario: Ii is calculated in equation Yi is the proportion of the population of region i vaccinated with only one dose of vaccine. 230 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2022. We extracted estimates of the infection fatality rate (IFR, for pre-Omicron and Omicron), natural 271 immunity protection against mortality following past COVID-19 infection, vaccine effectiveness 272 against mortality, and cost per dose of vaccine administered from the published literature (Table 273 2). 274 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2022. Given the uncertainty surrounding several model parameters, we sought to assess the robustness 286 of our conclusions under a wider range of assumptions about the values of our parameters alone 287 and in combination. We therefore conducted a sensitivity analysis assessing the number of deaths 288 averted and the cost-per-death averted while varying IFR, vaccine effectiveness, and vaccine 289 cost. We ranged IFR from a "high" estimate of 5/1,000 consistent with pre-Omicron levels, 22 to a 290 "low" estimate of 5/10,000, consistent with mortality reduction observed for Omicron in the 291 US. 24 We ranged vaccine effectiveness against mortality for the two-dose scenario from 80% to 292 95%, and for the three-dose scenario from 90% to 99%, given the uncertainty of vaccine 293 effectiveness against Omicron as well as potential future variants. 25 Vaccine cost was ranged 294 from $5 to $10 per dose (Table 1). 295 296 As a scenario analysis, we examined the value of vaccines under imperfect uptake. For this 297 analysis, avertible deaths were reduced from 100% to 75%, consistent with vaccine uptake 298 observed in the United States. Cost for vaccine production was kept at 100%, with the 299 assumption that enough vaccine is produced for full vaccination but uptake is reduced. 300 301 We also assessed the potential benefit of vaccination in a scenario of high prior infection with 302 COVID-19, since Omicron may spread through the world faster than vaccination can take place. 303 This sensitivity analysis assumed that 100% of the population in LIC/LMIC would be previously 304 infected by COVID-19 prior to vaccination, such that mortality risk is entirely among those with 305 partial natural protection . 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270465 doi: medRxiv preprint Base Case Analysis 323 324 For the two-dose scenario with base case parameter estimates, using excess mortality to estimate 325 prior infections and number at risk, scaling up vaccination to provide two doses of mRNA 326 vaccine to everyone in LIC/LMIC would cost $35.5 billion and avert 1.3 million deaths from 327 COVID-19, at a cost of $26,900 per death averted (Table 3) . Scaling up vaccination to provide 328 three doses of mRNA vaccine to everyone in LIC/LMIC would cost $61.2 billion and avert 1.5 329 million deaths from COVID-19 at a cost of $40,800 per death averted (Table 3) . 330 331 Sensitivity Analysis 332 333 We considered a wide range of values for IFR and vaccine effectiveness ( Table 2 ). For the two-334 dose scenario, the cost-per-death averted ranged from $4,500 when IFR was 5/1,000 and vaccine 335 effectiveness against mortality was 95%, to $53,800 when IFR was 5/10,000 and vaccine 336 effectiveness against mortality was 80% (Figure 1 ). Deaths averted with the same parameter 337 estimates ranged from 7.8 million to 0.7 million, respectively ( Figure 2 ). 338 339 Considering an IFR of 1/1,000 and a vaccine effectiveness of 80% with the two-dose scenario, 340 varying the cost-per-dose from $5 to $10 led to a range of cost-per-death estimates of $19,200 341 with a $5 cost-per-dose to $38,400 with a $10 cost-per-dose (Figure 1 ). 342 343 Examining the implication of this parameter uncertainty for the three-dose scenario, the cost-per-344 death averted ranged from $7,400 when IFR was 5/1,000 and vaccine effectiveness against 345 mortality was 99% to $81,500 when IFR was 5/10,000 and vaccine effectiveness against 346 mortality was 90% (Figure 1 ). Deaths averted with the same parameter estimates ranged from 8.3 347 million to 0.8 million, respectively ( Figure 2 ). 348 349 Considering an IFR of 1/1,000 and a vaccine effectiveness of 80% with the three-dose scenario, 350 varying the cost-per-dose from $5 to $10 led to a range of cost-per-death estimates of $29,100 351 with a $5 cost-per-dose to $58,200 with a $10 cost-per-dose ( Figure 1 ). 352 353 354 Vaccine Hesitancy Analysis 355 356 For the two-dose scenario with base case parameter estimates, using excess mortality to estimate 357 prior infections and number at risk, reducing vaccine uptake to 75% but keeping cost at 100% 358 would avert 1.0 million deaths at a cost of $25,900 per death averted. When considering a wide 359 range of values for IFR and vaccine effectiveness, cost-per-death averted ranged from $7,200 360 when IFR was 5/1,000 to $71,700 when IFR was 5/10,000. Deaths averted with the same 361 parameter estimates ranged from 5.0 million to 0.5 million, respectively. 362 363 For the three-dose scenario with base case parameter estimates, using excess mortality to 364 estimate prior infections and number at risk, reducing vaccine uptake to 75% but keeping cost at 365 100% would avert 1.2 million deaths at a cost of $53,400 per death averted. When considering a 366 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270465 doi: medRxiv preprint wide range of values for IFR and vaccine effectiveness, cost-per-death averted ranged from 367 $10,700 when IFR was 5/1,000 to $107,700 when IFR was 5/10,000. Deaths averted with the 368 same parameter estimates ranged from 4.7 million to 0.6 million, respectively. 369 370 371 All Previously Infected Scenario 372 373 We finally considered a scenario in which Omicron infects 100% of LIC/LMIC population 374 before vaccination is available, and all mortality risk occurs through re-infection. In this instance, 375 the three-dose scenario with natural immunity protection against mortality of 80% and base case 376 parameters leads to a cost-per-death averted at $115,000, with 0.5 million deaths averted. 377 378 When varying IFR and vaccine effectiveness against mortality, with a cost-per-dose of $7 cost-379 per-death averted ranged from $20,900 with an IFR of 5/1,000 and vaccine effectiveness against 380 mortality of 99% and $230,000 with and IFR of 5/10,000 and vaccine effectiveness against 381 mortality of 90%. Deaths averted with the same parameter estimates ranged from 2.9 million to 382 0.3 million, respectively . 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 9, 2022. ; https://doi.org/10.1101/2022.02.08.22270465 doi: medRxiv preprint Institute for Health Metrics and Evaluation (IHME). COVID-19 Mortality, 504 Infection,testing, Hospital resource Use, and Social Distancing Projections Assessing the Burden of COVID-19 in 508 Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications Clinical outcomes among 515 patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California Emergence in Southern France of a new SARS-CoV-2 518 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the 519 spike protein Systematic Review to Update 'Value of a 521 Statistical Life' Estimates for Australia US Department of Health and Human Services. Guidelines for Regulatory Impact 525 Analysis BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness 530 against Death from the Delta Variant IFR and vaccine effectiveness 597 against mortality in the two-dose scenario (first panel) and three-dose scenario (second panel). The y-axis shows cost-per-death averted in US$, the x-axis shows 598 cost per dose of vaccine in US$. Solid lines show IFR of 5/10,000, dotted line shows IFR of 1/10,000, and dashed lines show IFR of 5/1,000. Dark red lines show 599 baseline vaccine effectiveness (80% in two-dose scenario and 90% in three-dose scenario), and dark blue lines show high vaccine effectiveness Sensitivity analysis looking at deaths averted of vaccination LIC/LMIC, ranging IFR and vaccine effectiveness against mortality in the two-dose 610 scenario (first panel) and three-dose scenario (second panel). The y-axis shows deaths averted, in millions. The x-axis shows IFR. Dark red lines show baseline 611 vaccine effectiveness (80% in two-dose scenario and 90% in three-dose scenario), and dark blue lines show high vaccine effectiveness